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Background: Human mesenchymal stem cells (hMSC) have recently raised the attention because of their
therapeutic potential in the novel context of regenerative medicine. However, the safety of these new and
promising cellular products should be carefully defined before they can be used in the clinical setting, as. The
protein expression profile of these cells might reveal potential hazards associated with senescence and tumoral
transformation which may occur during culture. Proteomic is a valuable tool for hMSC characterization and
identification of possible changes during expansion.
Results: We used Surface Enhanced Laser Desorption/Ionization-Time Of Flight-Mass Spectrometry (SELDI-ToF-MS)
to evaluate the presence of stable molecular markers in adipose tissue-derived mesenchymal stem cells (AD-MSC)
produced under conditions of good manufacturing practices (GMP). Proteomic patterns of cells prepared were
consistent, with 4 up-regulated peaks (mass-to-charge ratio (m/z) 8950, 10087, 10345, and 13058) through
subculture steps (P0-P7) with similar trend in three donors. Among the differentially expressed proteins found in
the cytoplasmic and nuclear fractions, a cytoplasmic 10.1 kDa protein was upregulated during culture passages and
was identified as S100A6 (Calcyclin).
Conclusions: This study suggests for the first time that common variation could occur in AD-MSC from different
donors, with the identification of S100A6, a protein prevalently related to cell proliferation and cell culture
condition. These results support the hypothesis of common proteomic changes during MSCs expansion and could
give important insight in the knowledge of molecular mechanisms intervening during MSC expansion.
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Human mesenchymal stem cells (hMSC) include a mul-
tipotent population with the potential to differentiate
into several mesodermal cell types including osteogenic,
adipogenic and chondrogenic lineages [1-6]. The regen-
erative potential of hMSC has recently raised an enor-
mous interest in the novel field of cellular therapy,
especially for “no-option” chronic and degenerative dis-
eases. However, the safety of these very promising thera-
peutic approaches needs to be extensively studied and* Correspondence: emanuele.capra@biotrack.it
1Biotrack S.r.l, Parco Tecnologico Padano, Lodi, Italy
4Institute Biotrack S.r.l, Via Einstein 26900, Lodi, Italy
Full list of author information is available at the end of the article
© 2012 Capra et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe knowledge of the critical control points of cell prolif-
eration is still poor. Currently, bone marrow (BM) is the
main source of hMSC for both experimental and clinical
applications, but this source of hMSC has several limita-
tions: aspiration of BM is an invasive procedure and the
frequency and differentiation capacity of hMSC decline
with age, thus reducing their therapeutic potential [7].
An alternative source of hMSC is the adipose tissue
since its collection is easier and safer than BM. Adipose
derived MSC (AD-MSC) can differentiate into other
lineages [8] and they have angiogenic [9] and immuno-
suppressive properties [10]. hMSC were characterized
according to various parameters such as adherence to
plastic, differentiation capacity and phenotypic assaytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kers. These conventional characterization approaches
depicted hMSC as a homogeneous cell population while
hMSC appeared extremely heterogeneous by using
proteomic and transcriptomic analyses [11]. It has been
demonstrated that BM-MSC derived cellular clones with
different proliferative capacities have the same cell sur-
face markers by flow cytometry, but they express differ-
ent protein patterns [12] when studied with different
proteomic approaches. Characterization of hMSC using
different molecular techniques also revealed that the
cells show changes during the expansion which is ac-
companied by changes in cell markers expression over
the culture period [13]. Protein expression maps, created
using two-dimensional polyacrylamide gel electrophor-
esis for continuous subcultures of clonal BM-MSC up to
10 passages, also revealed variation in the proteome dur-
ing cell expansion [14]. However, these results obtained
on MSC clonal populations did not take into account
the biological variability between different donors having
peculiar molecular profiles. Whether the molecular pat-
terns variations may reflect intrinsic biological modifica-
tions during culture or could be shared by different
donors is still to be clarified. It is therefore mandatory to
monitor AD-MSC inter-individual variability that could
limit their application. Herein we report the protein pat-
tern observed in AD-MSC preparations isolated from
donors during cell expansion by means of high through-
put SELDI-ToF-MS.
Results
Cell culture expansion
AD-MSC were successfully obtained under GMP condi-
tions from lipoaspirates of three healthy donors. The
AD-MSC were analyzed during seven passages and
showed a spindle-shaped morphology in confluent-
wave-like layers and by flow cytometry they were found
to express the typical hMSC surface antigens such as
CD90, CD73, CD44, CD105, alpha-SMA, CD13, HLA-
ABC and SSEA4; most of the cells were also positive for
CD146 and platelet-derived growth factor receptor beta
(PDGFRβ). The cells were negative for hematopoietic
and endothelial markers (CD45, CD34, CD133; Figure 1)
and for HLA-DR, NG2 and NGFR. The immunopheno-
typic profile was stable during passages (see the repre-
sentative graphs in Figure 1) for all the donors. The
average population doublings for the three AD-MSC
lines are shown in Figure 1. The potential of the cells to
differentiate into three mesengenic cell lineages was con-
firmed by their ability to give rise to the adipogenic,
osteogenic and chondrogenic commitment after specific
differentiation protocols at passages three and five (data
not shown). Telomerase activity was assayed in the
AD-MSC. The AD-MSC had low telomerase activity whichremained approximately unchanged during each passage.
In comparison with the human cervical adenocarcinoma
cell line HELA (positive controls; Helen Lane, ATCC,
CCL-2, Manassas, VA) AD-MSC lines showed a much
lower telomerase activity (Figure 1).Protein profiling of AD-MSC from different donors
All AD-MSC preparations described above were ana-
lyzed on a CM10 (weak cation exchange) ProteinChip
array. AD-MSC were subjected to fractionation of cellu-
lar compartments in order to achieve an enrichment and
specific allocation of proteins that vary their expression
during subculturing, that results in distinctive spectra
exhibiting a variety of exclusive peaks (Figure 2). SELDI-
ToF-MS analysis includes longitudinal studies of succes-
sive cell culture passages as well as the comparison
between donors. Although the profiles appear homoge-
neous within each cell preparation, inter and intra-
individual variations in proteins expression were observed
as a consequence of cell expansion process. Donor-to-
donor variability was determined by a comparison of
mean correlation coefficients during serial culture passage.
The results revealed differences between individuals for
both fractions representing two different cellular compart-
ments. For the cytoplasmic fraction, the correlation coeffi-
cient for donors was between 0.78 and 0.98 and did not
change significantly during cell expansion. The nuclear
fraction showed a low correlation for each donor in com-
parison with the other two at passage 0 (0.33 and 0.50),
that significantly increased (P=0.0191) in the late passages
(0.91-0.98) (Figure 3).
For both fractions the protein profiles revealed a grad-
ual alteration among stages of expansion with samples
grouped based on passage number in early and late pas-
sages. In particular, cluster analyses of the cytoplasmic
extracts split the AD-MSC samples in two groups, P0-
P3 and P5-P7. Cluster analysis of the nuclear enriched
fraction grouped the AD-MSC from passage P0 to P2,
while passage P3, P4 and passage P5, P6, P7 were
divided in two subgroups (see Figure 4). Expression pro-
file revealed a total of 53 and 82 peaks detected in the
cytoplasmic and the nuclear fractions respectively. In
different passages of expansion 41.5% of cytoplasmic
peaks and 31.7% of nuclear peaks were differentially
expressed (P < 0.05) (Table 1; Additional file 1). These
protein peaks were however differently regulated during
the passages of expansion and between different donors
(data not shown), thereby only four of the significant
signals from the cytoplasmic fraction showed a common
trend and were up-regulated in late passages for all three
donors. The peaks with m/z 8,950, 10,087, 10,345 and
13,058 showed significantly increased levels of up to
5-folds during AD-MSC expansion (Figure 5).
Figure 1 AD-MSC characterization. A) Cumulative population doublings of 3 AD-MSC lines. B) Telomerase activity in AD-MSC. The RTA was
calculated from the different absorbances as follows: RTA= [(As sample-As heated-sample)]/[As Internal standard of the control template x 100]. It
is representative of telomerase activity of 3 AD-MSC lines from different donors (median and range). C) Representative AD-MSC
immunophenotype profile by flow cytometry at passages 4 and 7.
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Based on the marked differences in the intensities of the
four peaks at m/z 8,950, 10,087, 10,345 and 13,058 in cells
during expansion, we selected these proteins for further
characterization. Peaks isolation however resulted positiveonly for the most abundant peak at 10,087 m/z that was
then identified using tandem MS. In particular, analyses of
the corresponding chromatographic fraction revealed the
presence of several proteins within the peak at
10,180.7 Da closest in mass to that of the target signal and
Figure 2 SELDI-ToF spectra of protein extract from different cellular compartments.
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studies on telomerase-inhibited tumor cell lines identified
the peak at 10.1 kDa as the corresponding S100A6 protein
[15]. The peak was unambiguously allocated to the
S100A6 protein with a SELDI-ToF-MS immunocapture
assay by indirect coupling the anti-S100A6 antibody on
PS10 protein chip. Spectra from the protein extract bound
to the anti-S100A6 array resulted in a signal at 10.1 kDa;
conversely the unbound fraction showed a marked reduc-
tion in the intensity of the 10.1 kDa peak (Figure 6A).
Validation of m/z 10,087 levels by Western blot and ELISA
Up-regulation of S100A6 protein in all donors during
cell expansion was firstly validated by immuno-blotting
analysis using anti-S100A6 antibody. Late passages of
AD-MSC exhibited a significant increase in the amount
of S100A6 protein in comparison with passages 0 and 1
(Figure 6B). In particular from passage 0 to 7 the fold in-
crease of S100A6/Actin was 2.5, 10.5 and 2.0 for donor
1, donor 2 and donor 3 respectively (Figure 6C).
Ultimate validation of S100-A6 was performed by
Enzyme-Linked ImmunoSorbent Assays ELISA and
reported as absolute concentration (μg/ml). Similarly to
western-blot analysis, S100-A6 ELISA showed that the
level of calcyclin increases during subculturing. ELISA
showed a more homogeneous level of calcyclin protein
in each passage for all three donors with a mean fold in-
crease of 2.6 (SD 0.8) (Figure 6D).
Discussion
MSC are a promising tool for cellular therapy and they
are used as therapeutic cell products for different clinicalapplications, predominantly required to address degenera-
tive conditions, organ failure and tissue damage. However,
many parameters including heterogeneity of the initial
population, donor sources, donor age, and different proto-
cols for cell expansion make difficult the precise molecular
definition of primary MSCs. Currently there are no robust
approaches for verifying the status of the cells during
long-term in vitro culture [16-19]. In this context, the
need of rigorous standards for characterizing human
MSCs is very crucial and several studies are currently on-
going to reach this goal. Recently, new technologies in-
cluding the analysis of gene expression or proteomic
profiling have been suggested as methods to better define
MSC preparations [20-22]. In this article we describe the
use of SELDI-ToF technology to evaluate the proteomic
profile of AD-MSC and examine how this profile changes
during growth. SELDI-ToF-MS can detect multiple pro-
tein changes simultaneously with high sensitivity and spe-
cificity. The high-throughput nature and feasibility in
SELDI-TOF-MS experimental procedures made this tech-
nology useful for biomarker discovery [23,24], for the
characterization of different cell populations (T-cell and
fibroblast) [25,26] and with a great potential for clinical
perspectives. Other proteomic approaches, such as two-
dimensional gel electrophoresis, are more time consuming
and less suitable for processing a large number of sam-
ples at the same time [12,14]. AD-MSC profiles at dif-
ferent passages were compared using a technique
described as differential protein expression mapping,
whereby relative expression levels of proteins at specific
molecular weights were compared using a variety of statis-
tical techniques and bioinformatic software systems [27].
Figure 3 Donor-to-donor variability. Variation of the mean
correlation coefficients (Pearson’s correlation) between each donor
pair (D1: donor1, D2: donor2, D3: donor3) during subculturing
passages (P0-P7) for cytoplasmic and nuclear enriched fraction.
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profile of AD-MSC during passages.
In our experimental setting, the donor-related variability
was minimized by including only healthy subjects with
a close range of age. In addition, the isolation and GMP
culture procedures were very well standardized and
reproducible in order to reduce as much as possible
any operation/operator variability. This notwithstanding,
the AD-MSC immunophenotypic profile was extremely
homogenous during the passages and between the donors,
while the proteome profile was very dissimilar. In fact, the
hierarchical clustering analyses of protein profile demon-
strated considerable inter-individual differences that were
consistent with previous data obtained by using other
approaches as microarray assays [28]. By fractionating the
AD-MSC in the two compartments, cytoplasmic and nu-
clear, we increased the number of signals detected with apanel of protein peaks differentially expressed in three
donors in different passages of expansion. We observed a
different trend in the two compartments between donors
across different passages. The correlation between protein
profiles from different donors was maintained in each pas-
sage of expansion in the cytoplasmic fraction. On the con-
trary, the nuclear fraction showed a poor correlation in
one out of the three donors (Donor 3) at P0, while from
P1 all the donors had a good correlation with a marked
significant increase in protein profiling homogeneity from
P5 (Figure 3).
Cell expansion induced protein profiling alteration.
Following multivariate analyses the AD-MSC prepara-
tions were separated in two groups representing early
and late cell culture passages (Figure 4). These changes
during MSC long term culture are in line with data
reported by other authors and most likely reflect the
adaptation to the culture condition [20]. We found that
prolonged in vitro culture significantly altered the
AD-MSC proteomic phenotype, with many of the obser-
ved peaks showing significant variation during passages
in culture (Table 1; Additional file 1). Although nearly
one-third of the total peaks detected in the nuclear frac-
tion was differentially expressed, none showed a similar
variation in all the donors during AD-MSC expansion.
Protein profiling of cytoplasmic fraction revealed 22
peaks with highly significant changes in expression du-
ring passages; among these, only four protein peaks
(8,950, 10,087, 10,345 and 13,058 Da) showed a change
greater than 2 folds, with a progressive increase from
early to late passages for all the donors. Identification of
proteins is a major challenge in SELDI-ToF proteomic
profiling, however we could identify the most abundant
peak at 10,087 as S100A6 protein. Increase of S100A6
during cell expansion was confirmed also by western
blot and ELISA. S100 proteins are EF-hand calcium-
binding proteins that are involved in the regulation of
cellular processes such as cell proliferation, differenti-
ation, migration and apoptosis [29] and their expression
is functionally linked to cell cycle progression, cytoskel-
eton rearrangement [30], exocytosis [31] and other cel-
lular processes. An altered expression of calcyclin has
been also seen in different cancers even if its function
in tumor development still remains controversial [32,33].
S100A6, also known as calcyclin, modulates signaling
pathways by altering the binding potential or availability
of calcyclin specific target proteins [34]. Calcyclin is ex-
pressed in several cell types with different tissue specifi-
city: it is most abundant in fibroblasts and epithelial
cells [35], but it is also found in some neurons, astro-
cytes [36], smooth muscle cells [37], cardiac myocytes
[38] and thyrocytes [39]. Calcyclin expression in hMSC
has been seen in hair follicle bulb stem cells where it is
up regulated in follicle renewal in response to wounding
Figure 4 Graphical representation of cluster analyses of SELDI-ToF mass spectrometry. Peaks detected in AD-MSC from different donors
(1-2-3) during subculturing passages (from 0 to 7) indicated as donor_passage for A) cytoplasmic and B) nuclear enriched fraction. Red color
intensity, high expressed; green color intensity, low expressed.
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of calcyclin also in BM-MSC [41] and cord blood MSC
[42]. Calcyclin is frequently upregulated during prolife-
ration and differentiation and it is induced by diffe-
rent growth factors e.g. platelet-derived growth factor
(PDGF), epidermal growth factor (EGF) and serum [43].
Other S100 proteins were seen overexpressed by other
factors such as fibroblast growth factor (FGF-2) and
transforming growth factor-b (TGF-b) [44]. In line with
the finding reported in MSC from other sources, in the
present article we found that S100A6 protein levels
were overexpressed in AD-MSC during cell expansion.
S100A6 variation could be influenced by the in vitropropagation condition within other three protein peaks
at 8,950, 10,345 and 13,058 Da that were seen to be over
expressed during cell expansion. Furthermore, the com-
parative protein profiling clearly distinguished between
short and long term cultured AD-MSC, with cell pre-
parations that seem to become more homogeneous for
the nuclear compartment in late passages. Altogether
our findings suggest that common response occurs in
different donors during expansion, supporting the hy-
pothesis of progressive cellular adaptation to the culture
environment or clonal population selection during
in vitro expansion [20-45]. Nevertheless, if the protein
profiling variation in AD-MSC reflects only the long
Table 1 Differentially expressed peaks from different donors during subculturing passages detected in cytoplasmic
fraction by SELDI-ToF-MS
Mass/charge ratio Intensity average p-Value Mass/charge ratio Intensity average p-Value
11681,3 10,5 0,00510 4505,2 23,6 0,09294
10087,8 180,0 0,00596 4525,9 47,3 0,11063
13058,5 5,0 0,00647 4549,3 49,6 0,11699
10345,6 51,1 0,00827 3892,5 20,6 0,14944
8313,6 25,5 0,01110 12641,3 6,1 0,15640
11603,5 17,1 0,01370 3269,7 7,2 0,16163
8448,5 52,0 0,01433 3993,8 43,6 0,18409
13196,7 4,5 0,01639 4753,5 175,9 0,19162
11379,3 9,9 0,01656 2970,9 24,1 0,19704
8950,4 12,9 0,01801 8561,1 17,1 0,21491
12271,9 13,3 0,02701 7903,7 20,9 0,22520
10652,3 8,4 0,03273 9098,7 13,2 0,22695
3951,4 19,3 0,03273 14625,9 5,0 0,25075
11647,6 14,9 0,03336 4007,7 104,1 0,25748
3211,9 9,9 0,03957 4717,9 91,5 0,27237
11808,6 6,1 0,03995 3442,9 14,0 0,34329
11312,3 5,0 0,04187 4704,4 85,1 0,34450
3779,1 77,4 0,04267 4946,6 94,7 0,40701
9953,0 56,7 0,04599 4214,2 21,6 0,48495
3837,3 12,0 0,04685 4083,1 32,7 0,49240
7749,0 16,6 0,04729 3180,4 11,3 0,51660
4398,3 31,8 0,04909 6973,1 17,1 0,59677
6879,0 24,9 0,06410 2910,1 11,2 0,62746
10839,0 10,1 0,06498 4234,3 41,8 0,68760
7894,5 30,9 0,07050 3024,6 17,2 0,80993
13548,2 3,5 0,07475 4121,0 77,2 0,87368
4624,1 61,5 0,08248
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related to the microenvironment conditions still needs to
be clarified. Novel markers of MSC that would be linked
to specific biological behaviours that could be used as
quality controls in cell manufacturing process are
needed and SELDI-ToF protein profiling, by reflecting
the cell phenotype status, could be a useful tool to
monitor and characterize MSC cell during their expan-
sion in different conditions and help translating stem
cell technologies into routine clinical applications.
Conclusions
In conclusion, we observed changes in the proteomic
phenotype of AD-MSC following prolonged in vitro cul-
ture, which were consistent among cells from 3 donors. In
particular, the protein with the greatest change in expres-
sion during the cell culture was identified as S100A6 or
calcyclin. Although the exact nature of observed variationin protein profiles during culture is not known, it could
reflect a decrease in the complexity of initial AD-MSC
population, resulting in more homogeneous cell type, or
the changes may reflect adaptation of cells to their new
environment. Advances in proteomic profiling may iden-
tify molecular biomarkers to better characterize the
phenotypic features of MSC and hence increase the effec-
tiveness of their use in cell therapy.
Methods
AD-MSC isolation and expansion
Samples of lipoaspirate obtained from three healthy sub-
jects (age 25–50 years) after informed consent were asep-
tically collected in syringes and transported to the GMP
facility at controlled temperature. Soon after, the lipoaspi-
rate was transferred into a modified Top&Bottom triple
bag (Fresenius Kabi, Bad Homburg, Germany), diluted
and centrifuged with sterile phosphate-buffered saline
Figure 5 Protein peaks having a similar trend in all the three donors during AD-MSC expansion.
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blood cells. Then the sample was digested for 40 minutes
at 37°C with NB6 GMP grade collagenase (Nordmark
Arzneimittel GmbH&C, Uetersen, Germany). The diges-
tion was stopped using PBS and after centrifugation
(1185 g for 30 minutes) to discard the solid fat phase,
the stromal vascular fraction was seeded into a 1 layer
Cell Stack (Macopharma) in a complete medium (alpha
MEM, Macopharma; 10% fetal bovine serum, Australian
origin, gamma irradiated, Gibco Invitrogen Corporation,
Carlsbad, CA). After 24 hours, the non-adherent fraction
was removed and adherent cells were cultured in com-
plete medium. The cultures were maintained at 37°C in a
humidified atmosphere containing 5% CO2 and the me-
dium was changed twice a week. AD-MSC were cultured
until passage 7 in order to follow the proteomic modifi-
cations well after the passages at which these cells are
usually used for clinical application, that is passage 2–3.
Three AD-MSC lines were seeded (3000 cells/cm2), pas-
saged after detachment (TryPLE Select, Gibco Life
Technologies, Italy) and counted once they reached 80%
confluence. To evaluate the proliferative potential of AD-
MSC, the cumulative population doublings (CPD) rate
was determined using the following formula:
PD ¼ Log10 Nð Þ=Log10 2ð Þ
Where N is the ratio between the harvested cells and
the seeded cells. The PD for each passage was calculatedand added to the PD of the previous passages to gener-
ate data for CPD.
Detection of telomerase activity
Telomerase activity was investigated in order to evaluate
possible tumorigenic modifications in AD-MSC lines
from passage 0 to passage 7 using the TeloTAGGG Tel-
omerase PCR ELISA PLUS (Roche Applied Science,
Mannheim, Germany). AD-MSC layer was dissociated
by TryPLE Select and the cells were centrifuged at 300 g
for 10 minutes. AD-MSC pellets (2x105 cells) were
resuspended in 200 μL of lysis buffer and protein
extracts were obtained according to manufacturer’s
protocol. Each protein extract was divided into two ali-
quots before performing the assay: one was used as
negative control after heat inactivation of telomerase at
85°C for 10 minutes, the other one was used to evaluate
the telomerase by addition of telomeric sequence. In the
sample extracts telomerase was detected from the
addition of telomeric repeats to the 3’ end of a biotin-
labeled synthetic primer, and these elongation products
were amplified by PCR. To exclude false negative results
due to the presence of Taq DNA-polymerase inhibitors
present in the lysates, a 216 bp internal standard (IS)
was also amplified in the reaction mixture. The number
of hexamers added in each sample was then evaluated
by ELISA technique using TTAGGG specific probes to
reveal the telomerase activity. The level of telomerase
activity in each sample was determined by comparing
the signal from the sample with the signal obtained
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0.001 amol of template DNA having the same sequence
product with eight telomeric repeats. The relative tel-
omerase activity (RTA) was calculated from different
absorbances (Abs) as follows:RTA ¼ Absofsample absofheat  treatedsampleð Þ= AbsofISofthesampleð Þ
Absofcontroltemplate absoflysisbufferð Þ= AbsofISofthecontroltemplateð ÞFigure 6 Validation of S100A6 in cytoplasmic extract of AD-MSC. A) S
of AD-MSC at passage 7: 1) spotted on CM10 array; 2) spotted on PS10 arra
array indirectly coupled to anti-S100A6 antibody and spotted on CM10 arra
10,087. B) SDS-PAGE/Western blot analysis using anti-S100A6 and anti-Actin
different donors. C) Western blot densitometry quantification of the corresp
between S100A6 and Actin. D) Human S100-A6 ELISA quantification. ValueFlow cytometry analysis
One x106 AD-MSC at passage 4 and 7 were washed in
PBS for 20 minutes at RT and incubated in the dark with
the following directly conjugated mouse-anti human
antibodies: CD90-FITC (Becton Dickinson, BD, San Josè,ELDI-ToF immunoassay of m/z 10,087. Cytoplasmic extract from a pool
y indirectly coupled to anti-S100A6 antibody; 3) eluted from PS10
y. The signals enclosed by the rectangle represent the peak at m/z
antibody of AD-MSC during different passages of cell expansion for
onding S100A6. Values are expressed as relative intensity ratio
s are expressed as absolute quantification (μg/ml S100A6).
Capra et al. Proteome Science 2012, 10:46 Page 10 of 13
http://www.proteomesci.com/content/10/1/46CA), CD73-APC (Miltenyi Biotec, Gladbach, Germany),
CD44-FITC (BD), CD105-PE (Beckman Coulter, Fullerton,
CA, USA), alpha-SMA FITC (Sigma-Aldrich), CD13-PE
(BD), SSEA4-FITC (BD), CD45-PC7 (Beckman Coulter),
HLA-ABC FITC (Beckman Coulter), HLA-DR PE (BD),
CD34-FITC (Miltenyi), CD133-PE (Miltenyi), CD146-FITC
(Miltenyi), PDGFRbeta-PE (R&D Systems, Minneapolis,
MN, USA), NG2-PE (BD), NGFR-PE (BD). The isotype-
matched immunoglobulins IgG1-FITC (Beckman Coulter),
IgG1-PE (Beckman Coulter), IgG1-APC (Beckman Coulter)
and IgG1-PC7 (Beckman Coulter) were used as negative
controls under the same conditions. After staining, the cells
were washed once with PBS. At least 30,000 events were
acquired using the FC500 flow cytometer (Beckman
Coulter) and plots were generated using the CXP analysis
software (Beckman Coulter).
Cell lysis and fractionation
AD-MSC were suspended in hypotonic buffer (10 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2) in presence of a
cocktail of protease inhibitors (Complete Mini EDTA-
free, Roche Diagnostics GmbH, Mannheim, Germany)
and incubated for 20 minutes on ice. Cells were dis-
rupted by fine times sonication (10 sec pulse with 10 sec
pause) and then centrifuged at 15000 g for 10 minutes
(4°C) to obtain two fractions, according to previously
reported method with minor modifications [46]. Lysate
supernatant enriched in cytoplasmic proteins was stored
at −80°C, while the pellet, which was enriched in nuclear
protein, was resolubilized in buffer (Urea 9 M and 10%
β-mercaptoethanol) and stored at −80°C. Protein con-
centrations for each fraction were assessed by using
Bradford protein assay according to the manufacturer’s
instructions (Bio-Rad, Hercules, CA, USA).
Protein profiling
Cytoplasmic and nuclear protein extracts were loaded,
in triplicate, onto CM10 proteinchip surfaces (weak cat-
ionic exchange) as follows. Proteinchip surfaces in a Bio-
processor (Ciphergen Biosystems, Fremont, CA, USA)
were pre-activated with binding buffer (low-stringency
buffer 0.1 M sodium acetate pH 4) for 5 minutes.
Twenty micrograms of proteins were diluted to a final
volume of 100 μL with binding buffer and incubated for
45 minutes on the ProteinChips (Ciphergen Biosystems).
After incubation, the chips were washed with binding
buffer three times then with deionized water twice. At
the end, 1 μL of matrix (half saturated sinapinic acid dis-
solved in 50% ACN/0.5% TFA) was added twice and
arrays were analyzed with a ProteinChip Reader (PCS
4000; Ciphergen Biosystems). Each protein spot was ana-
lyzed with a setting of laser and focus mass adjusted
to optimize the detection of spectral regions between
2–15 kDa and 15–30 kDa. SELDI-ToF spectra weregenerated by averaging 900 laser shots and calibrated
using the all-in-one Protein standard II (hirudin BHVK
7.0 kDa; bovine cytochrome C 12.2 kDa; equine myoglo-
bin 17 kDa; bovine carbonic anhydrase 29 kDa; yeast
enolase 46.7; bovine albumin 66.4 kDa; and bovine IgG
proteins 147.3 kDa; Ciphergen Biosystems).
Protein purification and identification
AD-MSC cytoplasmic enriched fractions of passage 7
were pooled from each donor and were subjected to
chromatographic separation to yield partially purified
protein for identification. One-hundred micrograms of
proteins from cell lysates were fractionated using reverse
phase chromatography (Agilent mRP Hi-recovery pro-
tein column 4.6 X 50 mm) at 80°C by HPLC (Agilent
1200 Series) at 1 ml/min flow with buffer A, consisting
of 0.1% TFA/water (v/v). Proteins were eluted with a
binary gradient 0–100% buffer B consisting of 0.1%
TFA/Acetonitrile (v/v). The gradient used was: 5 minutes
in buffer A, 5.01-11 min 0–30% buffer B, 11.01-44 min
30–55% buffer B, 44.01-54 min 55–100% buffer B, the
column was washed with 100% buffer B for 4 min and
requilibrated with 100% buffer A for 10 minutes. The
proteins were detected at 220 nm and one minute frac-
tions were collected giving a total of 27 fractions (1 mL
volume fraction). The fractions were dried under vac-
uum using a “speedvac” and solubilized in 50μL of Pro-
teinChip U9 buffer (Bio-Rad). Each fraction was
transferred onto Proteinchip surfaces CM10 (Ciphergen
Biosystems) as previously described and analyzed by
SELDI-ToF-MS. The fraction enriched for the protein of
interest was digested with trypsin (sequencing grade,
Sigma-Aldrich). Tryptic digestion mixture was analyzed
by means of LC-MS approach, according to previously
reported conditions [47].
ImmunoAssay SELDI-TOF
Anti-S100A6 polyclonal antibody (Sigma-Aldrich) was
indirectly coupled to a PS10 (Carbonyldiimidazole
chemistry) array. Proteinchip surface of the PS10 array
was pre-activated with 50% acetonitrile for 1 minute and
10 mM PBS pH 8 for 1 minute. Protein G (0.4 mg/mL
in PBS pH 8) was incubated for 1 hour to form stable
covalent bonds with Carbonyldiimidazole and unreactive
sites on the chip array were blocked with an ethanola-
mine solution 1 M pH 8 for 30 minutes. Chip was
washed twice for 5 minutes with PBS buffer pH 8 con-
taining 0.1%(v/v) Tween 20 and then with PBS buffer
10 mM pH 8. Then, 2 μL of anti-S100A6 antibody
(0.05 mg/ml) were diluted 1:10 with coupling buffer
(100 mM PBS, 150 mM NaCl pH 7.5) and incubated
with the chip for one hour. Chip was then washed twice
for five minutes with PBS 10 mM pH 8 containing 0.1%
(v/v) Tween 20, once with PBS 10 mM pH 8 and once
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enriched fraction of passage 7 AD-MSC which had been
pooled from the 3 donors was mixed with TBS-T
(137 mM NaCl, 2.7 mM KCl, 25 mM Tris and 0.05%(v/v)
Tween 20) and was loaded on PS10 chip. The lysate was
incubated for 1.5 hours and the unbound fraction was
eluted and collected. Chip was washed twice for 5 minutes
with TBS pH 8 containing 0.1% (v/v) Tween 20, once with
TBS pH 8 and once with 10 mM HEPES pH 7. At the end
of the washes, 1μL of matrix (half saturated sinapinic acid
dissolved in 50% ACN/0.5% TFA) was added twice and
array was analyzed with a ProteinChip Reader. The un-
bound fraction was processed on Proteinchip surfaces
CM10 as described previously and analyzed by SELDI-
ToF-MS.
SDS-Page/wester bloting analysis
Western blot analysis was performed on AD-MSC from
each donor independently at passages P0, P1, P4, P7. At
first, 5 μg of cytoplasmic lysates were added to Laemmli
buffer 4X (8% SDS, 250 mM Tris–HCl pH 6.8, 40% gly-
cerol, 20% β-mercaptoethanol and 0.1% blue of bromo-
phenol) to obtain a 1X solution. The solution was
heated to 100°C in a water bath for 5 minutes and was
loaded on 18% SDS-polyacrylamide Gel (Biorad), run-
ning buffer was 25 mM Tris, 192 mM glycine 0.1% SDS,
external buffer was 25 mM Tris, 192 mM glycine. Fol-
lowing electrophoresis proteins were transferred onto
nitrocellulose membrane (Whatman, Dassel, Germany).
Nitrocellulose membrane was blocked with BSA 5% and
incubated overnight with primary anti-S100A6 antibody
and anti-Actin antibody (Sigma). Detection was per-
formed using anti Rabbit IgG alkaline phosphatase anti-
body (Sigma-Aldrich). Primary and secondary antibodies
were used at dilutions of 1/1,000 and 1/5,000, respect-
ively. Proteins were visualized by SIGMAFAST Fast Red
TR/Naphthol AS-MX tablets.
Human S100-A6 ELISA
S100A6 levels were determined using Human-S100-A6
ELISA kit (BioVendor-Laboratorni medicina a.s. Brno
Czech Republic) according to the manufacturer’s
instructions. ELISA was performed by using AD-MSC
cytosolic extracts at dilution 1/2,500 from each donor
for passages P0, P1, P4, P7.
Data analysis
Ciphergen Express software (version 3.5, Ciphergen Bio-
systems) was used for pre-processing data i.e. automatic
peak detection after baseline subtraction and adjustment
(S/N ratio > 5, cluster mass window 0.3% peak width).
The program also allows basic statistical analysis, includ-
ing hierarchical clustering, group scatter plots, P-values
(t-test statistics). The Mann–Whitney test was used tocompare peak intensities among the AD-MSC samples
(P value < 0.05). Additionally, multivariate analysis was
carried out using relative peak intensity and was applied
to the data set to identify groups and classification of
different AD-MSC preparation. The coefficient of correl-
ation was calculated including all peaks detected (53 for
cytoplasmic and 82 for nuclear fraction).
A Pearson correlation coefficient was calculated for
each donor in comparison with the other two at the
same passage. One-way analysis of variance (ANOVA)
was used to determine significance of difference in cor-
relation with different passages. These statistical analyses
were performed using Graphad Prism v 5.0 for Windows
(GraphPad Software, San Diego, USA) on exported raw
data that were previously converted using a square root
transformation to a normal distribution [48].
Additional file
Additional file 1: Differentially expressed peaks from different
donors during subculturing passages detected in nuclear fraction
by SELDI-ToF-MS.
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